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• The COVID-19 pandemic and restrictions on travel and gathering have likely had major
impacts on drug supply, use and harms [1] and there have been significant challenges with
delivery of drug treatment and harm reduction services [2].
• People who use drugs may also be at increased risk of COVID-19 transmission because
of the social nature of drug procurement and use.
• There have been urgent calls for evidence regarding the experiences of people who use
drugs during the COVID-19 pandemic to inform public health efforts.
• The Ecstasy and Related Drugs Reporting System (EDRS) is an illicit drug monitoring
system which has operated in Australia since 2003, and includes annual interviews with
people who regularly use ecstasy and other illicit stimulants [3].
• Recognising the critical need for information, the EDRS project has been adapted to
collect important data on people’s experiences during COVID-19.
• This output represents findings from 805 interviews (101 ACT, 100 NT, 103 NSW, 100
QLD, 101 SA, 100 TAS, 100 VIC, 100 WA) undertaken between 25th April and 31st July
2020, as part of the EDRS.
• EDRS interviews are with a sentinel sample of people aged 18 or older who have used
ecstasy and other illicit stimulants at least once monthly in the preceding six months and
resided in a capital city for the last 12 months.
• Participants are recruited via social media and peer referral, complete a one hour
interview, and are reimbursed $40 for time and expenses.
• In 2020, interviews were completed via phone or videoconference (instead of face-to-face)
and participants were reimbursed electronically to manage risk of COVID-19 transmission.
• The interview length was reduced and content adapted to include COVID-19 specific
items, anchored to implementation of restrictions in Australia at the beginning of March
2020. The study protocol remained otherwise unchanged.
• The sample interviewed are demographically similar to those recruited in 2019 and in
earlier years, being mostly male (61%) and young (median age 22; IQR 19-27).
Social impacts of COVID-19
• 14% said their living situation had changed since the beginning of March 2020.
• 27% said they were receiving more income (from any source) in the past month as
compared to the month of February 2020, 36% less money, and 37% a similar amount.
Experience of COVID-19 testing, diagnosis and restrictions
• 9% said they had been tested for COVID-19. None had been diagnosed with COVID-19.
• 80% reported home isolation (i.e., staying at home and only leaving for essential activities)
and 7% being in quarantine since March 2020.
• At interview, the majority (62%) had been practicing home isolation for 5 weeks.
• 32% were currently worried about contracting COVID-19.
Changes in drug use with COVID-19 restrictions
• 37% of participants reported that the main drug they used in the past month was different
to the main drug they used in February 2020. The most common change was from
reporting ecstasy/MDMA in February to cannabis in the past month.
• 69% reported a change in frequency of use of ecstasy/MDMA and related drugs in the past
month relative to frequency of use in February 2020. The majority of these (75%) reported
reducing or ceasing their use.
• Participants who reported past six month use of each drug were asked about changes in
their use since the beginning of March 2020 compared to before. Participants most
commonly reported reducing use of ecstasy/MDMA, and no change in use of
benzodiazepines, e-cigarettes and LSD (Figure 1).
• Primary reasons cited for decreasing use comprised fewer opportunities to be with
people/go out and “didn’t feel like it”, and for increasing use comprised “more bored” and
“more time”, although these vary across substances.
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Figure 1. Change in drug use since March 2020 compared to before amongst people who report use in the past
six months. Estimates reflect non-prescribed use for pharmaceutical medicines.
Perceived availability of substances
• Participants were asked about the perceived availability of substances since March 2020
as compared to before (Figure 2).
• Participants most commonly reported MDMA pills and crystal methamphetamine as harder
to obtain, and the remaining drugs as relatively stable.
• 22% of participants reported being concerned about not being able to access illicit drugs
because of COVID-19 restrictions.











More difficult Stable Easier Fluctuates
Figure 2. Change in perceived availability since March 2020 as compared to before, amongst those confident
commenting. ‘Don’t know’ responses are excluded.
Obtaining illicit drugs
• 65% reported no change in their means of obtaining illicit drugs since the beginning of
March 2020.
• Most common changes in means of obtaining illicit drugs since March 2020 reported
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Physical and mental health
• 18% reported experiencing a stimulant overdose in the past 12 months (14% before
March, 3% since March, and 1% both before and since March).
• 6% reported being in drug treatment in the past 6 months (4% before March, 1% since
March, and ≤5 both before and since March).
• 4% reported any difficulties in accessing health services for alcohol and/or drug support
since March.
• 41% rated their mental health as worse in the past month compared to February 2020;
33% rated it as similar, and 26% as better.
Precautions to reduce COVID-19 transmission and impacts of restrictions on
drug acquisition and use
• 12% of participants reported directly seeking information on reducing COVID-19
transmission risk while using drugs or how to avoid impacts of restrictions on drug
procurement and use. Common sources of information were social media and online
forums.
• Participants were asked about changing a range of behaviours explicitly to reduce COVID-
19 transmission risk or impacts of restrictions when using or acquiring drugs. Most
commonly endorsed responses include:
Yes
43%
Washed hands with 




Avoided sharing drug use 




Stocked up on illicit/non-
prescribed drugs
• Most participants reported no change or a decrease in their illicit drug use since COVID-19
restrictions compared to before March 2020, although changes in use varied by drug.
Perceptions of illicit drug availability were mostly that it remained stable.
• Participants reported negative impacts on mental health, but only a small number reported
difficulties engaging with services for alcohol and drug-related reasons. Participants
reported changing behaviours to reduce the risk of COVID-19 transmission while using
drugs.
• It is critical to continue to monitor impacts, particularly amongst those populations who
report more regular or dependent use of drugs (e.g., through the Illicit Drug Reporting
System and SuperMIX interviews with people who regularly inject drugs).
• More extensive findings on COVID-19 impacts will be reported in future outputs from the
project.
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